Literature DB >> 12900527

Intravenous nitroglycerin in the management of retained placenta.

Peter A Chedraui1, Daniel F Insuasti.   

Abstract

Thirty patients in the third stage of delivery complicated by retained placenta were prospectively managed with intravenous nitroglycerin. We studied the effect of nitroglycerin on the hemodynamics and characteristics of the procedure, and also analyzed labor and maternal and neonatal data. Intravenous nitroglycerin effectively aided the extraction of the retained placenta in all cases. The average procedure time was 5.3 +/- 1.1 min, and the dose range was 50-200 microg. Systolic and diastolic blood pressure fell significantly from 111 +/- 7.5 to 103 +/- 6 mm Hg and from 74 +/- 6.7 to 67 +/- 6.6 mm Hg, respectively (p<0.05). Although statistically significant, this was not evident clinically and there were no complications. Intravenous nitroglycerin at a dose of 200 microg or less is safe, effective and predictable in the management of retained placenta and could obviate the need of general anesthesia. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900527     DOI: 10.1159/000072734

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  10 in total

1.  Glyceryl trinitrate to reduce the need for manual removal of retained placenta following vaginal delivery: the GOT-IT RCT.

Authors:  Fiona C Denison; Kathryn F Carruthers; Jemma Hudson; Gladys McPherson; Graham Scotland; Sheonagh Brook-Smith; Cynthia Clarkson; Mathilde Peace; Jane Brewin; Gin Nie Chua; Nina Hallowell; Jane E Norman; Julia Lawton; John Norrie
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

2.  In Vitro Assessment of the Antimicrobial Efficacy of Optimized Nitroglycerin-Citrate-Ethanol as a Nonantibiotic, Antimicrobial Catheter Lock Solution for Prevention of Central Line-Associated Bloodstream Infections.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Cheryl Hirsh-Ginsberg; Kimberly Murray; Anne-Marie Chaftari; Ray Hachem; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Nitroglycerin for management of retained placenta: a multicenter study.

Authors:  Maria Bullarbo; Hans Bokström; Håkan Lilja; Elisabeth Almström; Nina Lassenius; Agneta Hansson; Erling Ekerhovd
Journal:  Obstet Gynecol Int       Date:  2012-05-22

4.  Obstetric use of nitroglycerin: Anesthetic implications.

Authors:  Richa Saroa; Shikha Sachan; Sanjeev Palta; Satinder Gombar; Nitika Sahai
Journal:  Saudi J Anaesth       Date:  2013-07

5.  Hysterotomy for retained placenta in a septate uterus: a case report.

Authors:  Daniel Lee; Joseph Johnson
Journal:  Case Rep Obstet Gynecol       Date:  2012-06-07

6.  Myomectomy for retained placenta due to incarcerated fibroid mass.

Authors:  S U Mbamara; Abc Daniyan; Ejenobo Osaro; I C Mbah
Journal:  Ann Med Health Sci Res       Date:  2015 Mar-Apr

7.  Retained placenta after vaginal delivery: risk factors and management.

Authors:  Nicola C Perlman; Daniela A Carusi
Journal:  Int J Womens Health       Date:  2019-10-07

Review 8.  Use of nitroglycerin for parallel transverse uterine cesarean section in patients with pernicious placenta previa and placenta accrete and predicted difficult airway: A case report and review of literature.

Authors:  Yushan Ma; Yong You; Xiaoqin Jiang; Xuemei Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 9.  Nitroglycerin for management of retained placenta.

Authors:  Hany Abdel-Aleem; Mahmoud A Abdel-Aleem; Omar M Shaaban
Journal:  Cochrane Database Syst Rev       Date:  2015-11-12

10.  Nitroglycerin for treatment of retained placenta: A randomised, placebo-controlled, multicentre, double-blind trial in the UK.

Authors:  Fiona C Denison; Kathryn F Carruthers; Jemma Hudson; Gladys McPherson; Gin Nie Chua; Mathilde Peace; Jane Brewin; Nina Hallowell; Graham Scotland; Julia Lawton; John Norrie; Jane E Norman
Journal:  PLoS Med       Date:  2019-12-30       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.